TY - JOUR
T1 - Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling
AU - Nazio, Francesca
AU - Po, Agnese
AU - Abballe, Luana
AU - Ballabio, Claudio
AU - Diomedi Camassei, Francesca
AU - Bordi, Matteo
AU - Camera, Antonio
AU - Caruso, Simona
AU - Caruana, Ignazio
AU - Pezzullo, Marco
AU - Ferraina, Caterina
AU - Milletti, Giacomo
AU - Gianesello, Matteo
AU - Reddel, Sofia
AU - De Luca, Carmen Dolores
AU - Ceglie, Donatella
AU - Marinelli, Sara
AU - Campello, Silvia
AU - Papaleo, Elena
AU - Miele, Evelina
AU - Cacchione, Antonella
AU - Carai, Andrea
AU - Vinci, Maria
AU - Velardi, Enrico
AU - De Angelis, Biagio
AU - Tiberi, Luca
AU - Quintarelli, Concetta
AU - Mastronuzzi, Angela
AU - Ferretti, Elisabetta
AU - Locatelli, Franco
AU - Cecconi, Francesco
PY - 2021
Y1 - 2021
N2 - Medulloblastoma (MB) is a childhood malignant brain tumour comprising four main subgroups characterized by different genetic alterations and rate of mortality. Among MB subgroups, patients with enhanced levels of the c-MYC oncogene (MBGroup3) have the poorest prognosis. Here we identify a previously unrecognized role of the pro-autophagy factor AMBRA1 in regulating MB. We demonstrate that AMBRA1 expression depends on c-MYC levels and correlates with Group 3 patient poor prognosis; also, knockdown of AMBRA1 reduces MB stem potential, growth and migration of MBGroup3 stem cells. At a molecular level, AMBRA1 mediates these effects by suppressing SOCS3, an inhibitor of STAT3 activation. Importantly, pharmacological inhibition of autophagy profoundly affects both stem and invasion potential of MBGroup3 stem cells, and a combined anti-autophagy and anti-STAT3 approach impacts the MBGroup3 outcome. Taken together, our data support the c-MYC/AMBRA1/STAT3 axis as a strong oncogenic signalling pathway with significance for both patient stratification strategies and targeted treatments of MBGroup3.
AB - Medulloblastoma (MB) is a childhood malignant brain tumour comprising four main subgroups characterized by different genetic alterations and rate of mortality. Among MB subgroups, patients with enhanced levels of the c-MYC oncogene (MBGroup3) have the poorest prognosis. Here we identify a previously unrecognized role of the pro-autophagy factor AMBRA1 in regulating MB. We demonstrate that AMBRA1 expression depends on c-MYC levels and correlates with Group 3 patient poor prognosis; also, knockdown of AMBRA1 reduces MB stem potential, growth and migration of MBGroup3 stem cells. At a molecular level, AMBRA1 mediates these effects by suppressing SOCS3, an inhibitor of STAT3 activation. Importantly, pharmacological inhibition of autophagy profoundly affects both stem and invasion potential of MBGroup3 stem cells, and a combined anti-autophagy and anti-STAT3 approach impacts the MBGroup3 outcome. Taken together, our data support the c-MYC/AMBRA1/STAT3 axis as a strong oncogenic signalling pathway with significance for both patient stratification strategies and targeted treatments of MBGroup3.
KW - Autophagy
KW - Brain tumours
KW - Cancer stem cells
KW - Therapy
KW - Autophagy
KW - Brain tumours
KW - Cancer stem cells
KW - Therapy
UR - http://hdl.handle.net/10807/228263
U2 - 10.1007/s00401-021-02347-7
DO - 10.1007/s00401-021-02347-7
M3 - Article
SN - 0001-6322
VL - 142
SP - 537
EP - 564
JO - Acta Neuropathologica
JF - Acta Neuropathologica
ER -